페이지 정보
본문
By blocking PDE5, cialis 30 mg Viagra enhances the effects of NO by prolonging the duration and effect of cGMP, thus improving the ability to achieve and maintain an erection in the presence of sexual stimulation. Viagra works by inhibiting an enzyme known as phosphodiesterase type 5 (PDE5), which is responsible for the breakdown of cGMP in the corpus cavernosum. PDE5, however, breaks down cGMP, thus inhibiting the ability to achieve or maintain an erection. The drug is effective only with sexual stimulation, as it relies on the initial release of nitric oxide by the body.
By inhibiting PDE5, Viagra effectively increases the levels of cGMP, enhancing and prolonging erections in men suffering from ED. PDE5 breaks down cGMP, thus inhibiting erectile function; Viagra counters this by reducing the activity of PDE5, enhancing erectile response when a man is sexually stimulated. Under normal circumstances, upon sexual stimulation, nitric oxide (NO) is released in the corpus cavernosum. The primary mechanism by which Viagra operates is through the inhibition of the enzyme phosphodiesterase type 5 (PDE5), which is found predominantly in the corpus cavernosum, the spongy tissue of the penis.
cGMP causes the smooth muscles of the corpus cavernosum to relax, leading to an inflow of blood and an erection. NO activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP). This process allows for increased blood flow into the penis, facilitating the achievement and maintenance of an erection. By blocking this enzyme, sildenafil increases the levels of cyclic guanosine monophosphate (cGMP), leading to relaxation of smooth muscle cells in the penile arteries and the corpus cavernosum.
The mechanism of action of Viagra involves the inhibition of the enzyme phosphodiesterase type 5 (PDE5) which is found primarily in the penis. Originally developed by scientists at Pfizer as a potential treatment for hypertension and angina, Viagra’s profound impact on erectile function transformed it into the first oral treatment approved by the FDA for erectile dysfunction in 1998. Viagra, scientifically known as sildenafil citrate, is a pharmaceutical drug that has revolutionized the treatment of erectile dysfunction (ED) since its serendipitous discovery in the late 1990s.
Erectile dysfunction is a condition where there is a difficulty in achieving or maintaining an erection suitable for sexual intercourse. It can stem from both psychological and physiological causes, including diabetes, cardiovascular disease, hormonal imbalances, and psychological factors such as anxiety or depression. Viagra’s role in treating this condition lies in its effects on blood flow. Research is ongoing into other possible therapeutic uses, including its effects on heart disease, diabetes-induced kidney damage, and even certain types of cancer.
For this indication, the drug is marketed under the name Revatio. Beyond its use in erectile dysfunction, Viagra has also been explored for other medical conditions. It has shown potential in treating pulmonary arterial hypertension (PAH), a rare but serious disease that affects the blood vessels in the lungs. In PAH, the blood vessels in the lungs are narrowed, blocked, or destroyed, leading to difficulty in oxygenating blood. It has shown potential benefits in treating pulmonary arterial hypertension (PAH), a rare but severe form of high blood pressure in the lungs.
By inhibiting PDE5, Viagra effectively increases the levels of cGMP, enhancing and prolonging erections in men suffering from ED. PDE5 breaks down cGMP, thus inhibiting erectile function; Viagra counters this by reducing the activity of PDE5, enhancing erectile response when a man is sexually stimulated. Under normal circumstances, upon sexual stimulation, nitric oxide (NO) is released in the corpus cavernosum. The primary mechanism by which Viagra operates is through the inhibition of the enzyme phosphodiesterase type 5 (PDE5), which is found predominantly in the corpus cavernosum, the spongy tissue of the penis.
The mechanism of action of Viagra involves the inhibition of the enzyme phosphodiesterase type 5 (PDE5) which is found primarily in the penis. Originally developed by scientists at Pfizer as a potential treatment for hypertension and angina, Viagra’s profound impact on erectile function transformed it into the first oral treatment approved by the FDA for erectile dysfunction in 1998. Viagra, scientifically known as sildenafil citrate, is a pharmaceutical drug that has revolutionized the treatment of erectile dysfunction (ED) since its serendipitous discovery in the late 1990s.
Erectile dysfunction is a condition where there is a difficulty in achieving or maintaining an erection suitable for sexual intercourse. It can stem from both psychological and physiological causes, including diabetes, cardiovascular disease, hormonal imbalances, and psychological factors such as anxiety or depression. Viagra’s role in treating this condition lies in its effects on blood flow. Research is ongoing into other possible therapeutic uses, including its effects on heart disease, diabetes-induced kidney damage, and even certain types of cancer.
For this indication, the drug is marketed under the name Revatio. Beyond its use in erectile dysfunction, Viagra has also been explored for other medical conditions. It has shown potential in treating pulmonary arterial hypertension (PAH), a rare but serious disease that affects the blood vessels in the lungs. In PAH, the blood vessels in the lungs are narrowed, blocked, or destroyed, leading to difficulty in oxygenating blood. It has shown potential benefits in treating pulmonary arterial hypertension (PAH), a rare but severe form of high blood pressure in the lungs.
댓글목록
등록된 댓글이 없습니다.